证券之星消息，11月14日生物制品板块较上一交易日上涨0.3%，金迪克领涨。当日上证指数报收于 3990.49，下跌0.97%。深证成指报收于13216.03，下跌1.93%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688670 | 金克 | 28.03 | 19.99% | 10.55万 | | 2.70亿 | | 301207 | 华兰婷审 | 25.38 | 7.22% | 33.68万 | | 8.59 Z | | 300485 | 赛开药业 | 13.35 | 4.54% | 38.27万 | | 5.13亿 | | 616889 | 欧林生物 | 24.81 | 4.29% | 10.93万 | | 2.71亿 | | 300357 | 我武生物 | 33.65 | 3.03% | 9.63万 | | 3.23亿 | | 603087 | 甘李药业 | 67.25 | 2.00% | 14.08万 | | 9.53亿 | | 68 ...

康弘药业今年以来股价涨70.47%，近5个交易日涨2.96%，近20日跌7.09%，近60日跌27.20%。 今年以来康弘药业已经1次登上龙虎榜，最近一次登上龙虎榜为7月21日。 资料显示，成都康弘药业集团股份有限公司位于四川省成都市金牛区蜀西路108号，成立日期1996年10 月3日，上市日期2015年6月26日，公司主营业务涉及化学药、中成药及生物制品的研发、生产与销售。 主营业务收入构成为：生物药54.83%，中成药32.49%，化学药12.50%，其他0.15%，其他(补 充)0.03%。 11月13日，康弘药业盘中上涨2.08%，截至10:34，报32.39元/股，成交1.39亿元，换手率0.63%，总市值 298.42亿元。 资金流向方面，主力资金净流出629.42万元，特大单买入441.31万元，占比3.19%，卖出468.86万元，占 比3.38%；大单买入1923.93万元，占比13.89%，卖出2525.80万元，占比18.23%。 康弘药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：阿尔茨海默、眼科 概念、创新药、生物医药、医疗器械等。 机构持仓方面，截止2025 ...

分红方面，康弘药业A股上市后累计派现20.38亿元。近三年，累计派现10.40亿元。 康弘药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：阿尔茨海默、眼科 概念、创新药、生物医药、医疗器械等。 康弘药业今年以来股价涨69.79%，近5个交易日涨3.30%，近20日跌7.99%，近60日跌23.52%。 今年以来康弘药业已经1次登上龙虎榜，最近一次登上龙虎榜为7月21日。 资料显示，成都康弘药业集团股份有限公司位于四川省成都市金牛区蜀西路108号，成立日期1996年10 月3日，上市日期2015年6月26日，公司主营业务涉及化学药、中成药及生物制品的研发、生产与销售。 主营业务收入构成为：生物药54.83%，中成药32.49%，化学药12.50%，其他0.15%，其他(补 充)0.03%。 截至10月20日，康弘药业股东户数2.49万，较上期增加3.53%；人均流通股27592股，较上期减少 3.41%。2025年1月-9月，康弘药业实现营业收入36.24亿元，同比增长6.23%；归母净利润10.33亿元，同 比增长6.08%。 11月12日，康弘药业盘中上涨2.06%，截至09:49， ...

董秘回答(康弘药业SZ002773)： 尊敬的投资者，您好！除了在研产品的海外临床试验推进外，公司旗下康柏西普眼用注射液（商品名： 朗沐）已在蒙古国、巴基斯坦、中国澳门实现销售，并随中国援外医疗队出征乍得、圭亚那、纳米比 亚、多米尼克等国。感谢您的关注与支持！查看更多董秘问答>> 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 投资者提问： 董秘你好！感谢你的耐心回复！贵公司有无进入其他国家的计划？若有，会采用什么策略？谢谢！ ...

免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 登录新浪财经APP 搜索【信披】查看更多考评等级 投资者提问： 该公司股票一直下跌，请问贵公司有什么措施保证自己的股票稳定？ 董秘回答(康弘药业SZ002773)： 尊敬的投资者，您好！二级市场股价受宏观经济、行业政策、市场情绪等多种因素共同影响，公司未来 将持续致力于以下几个方面的工作：1、公司深耕主营业务，提升经营绩效；2、强化信息披露，增进市 场认同；3、完善公司治理，保障股东权益；4、关注市场动态，传递公司价值。感谢您对公司的关注。 查看更多董秘问答>> ...

资料显示，成都康弘药业集团股份有限公司位于四川省成都市金牛区蜀西路108号，成立日期1996年10 月3日，上市日期2015年6月26日，公司主营业务涉及化学药、中成药及生物制品的研发、生产与销售。 主营业务收入构成为：生物药54.83%，中成药32.49%，化学药12.50%，其他0.15%，其他(补 充)0.03%。 康弘药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：阿尔茨海默、眼科 概念、创新药、生物医药、医疗器械等。 截至10月20日，康弘药业股东户数2.49万，较上期增加3.53%；人均流通股27592股，较上期减少 3.41%。2025年1月-9月，康弘药业实现营业收入36.24亿元，同比增长6.23%；归母净利润10.33亿元，同 比增长6.08%。 11月10日，康弘药业盘中上涨2.05%，截至13:24，报31.79元/股，成交1.47亿元，换手率0.68%，总市值 292.89亿元。 资金流向方面，主力资金净流出401.84万元，特大单买入325.02万元，占比2.21%，卖出0.00元，占比 0.00%；大单买入1508.29万元，占比10.26%，卖出2235 ...

Core Insights - The "2025 Sichuan Top 100 Private Enterprises" list was released, with Tongwei Group ranking first for the first time [1] - Significant changes in rankings were noted compared to the 2024 list, with Tongwei Group's revenue exceeding 240 billion yuan, moving up one position [1][2] - The threshold for entry into the list was set at 3.945 billion yuan, an increase of nearly 200 million yuan from the previous year [2] Group 1: Rankings and Revenue - The top 10 companies in the 2025 list include Tongwei Group, Qiya Group, New Hope Liuhe, Sichuan Chuanwei Group, and others [1] - The total revenue of private enterprises reached 1.74 trillion yuan, with 61 companies experiencing revenue growth [2] - The net profit of private enterprises totaled 52.04 billion yuan, with 43 companies increasing their net profit [2] Group 2: Manufacturing Sector - Manufacturing is the main support for the top 100 enterprises, with 73 companies in this sector, contributing 1.39 trillion yuan in revenue, accounting for 80.3% of the total [5] - The total assets of manufacturing enterprises also reached 1.39 trillion yuan, representing 79.3% of the total, with a significant increase of 16.4% from the previous year [5] - Tax contributions from manufacturing enterprises amounted to 45.668 billion yuan, making up 83.4% of the total [5] Group 3: Additional Rankings - The top 10 companies in the 2025 Sichuan Manufacturing Private Enterprises list mirror the top 10 of the overall list [5] - The top 10 companies in the 2025 Sichuan Service Industry Private Enterprises list include Chengdu JD Century Trading and others [6] - The top 10 companies in the 2025 Sichuan Private Enterprises R&D Investment list feature Tongwei Group and several pharmaceutical companies [6] Group 4: Economic Impact - Sichuan's GDP ranked fifth nationally, with the private economy contributing significantly, accounting for 56.4% of the total economic output [7] - The added value of the private economy reached 3.646 trillion yuan, reflecting a slight increase from the previous year [7]

Core Viewpoint - The A-share market saw a collective decline in innovative drug concept stocks, with significant drops in several companies' stock prices, indicating a negative trend in this sector [1]. Group 1: Stock Performance - Changshan Pharmaceutical (300255) experienced a decline of over 19%, with a total market capitalization of 51.7 billion and a year-to-date increase of 181.54% [2]. - Baicheng Pharmaceutical (301096) fell by 7.32%, with a market cap of 6.984 billion and a year-to-date increase of 68.53% [2]. - Baiyang Pharmaceutical (301015) decreased by 7.22%, with a market cap of 13.3 billion and a year-to-date increase of 9.05% [2]. - Other notable declines include: - Bibet-U (688759) down 5.82% with a market cap of 14.3 billion and a year-to-date increase of 79.30% [2]. - Kangchen Pharmaceutical (603590) down 5.81% with a market cap of 7.359 billion and a year-to-date increase of 100.18% [2]. - Kanghong Pharmaceutical (002773) down 5.71% with a market cap of 28.8 billion and a year-to-date increase of 62.53% [2]. - Shanghai Yizhong down 5.48% with a market cap of 11.4 billion and a year-to-date increase of 37.78% [2]. - Guosheng Pharmaceutical (300436) down 5.46% with a market cap of 17.9 billion and a year-to-date increase of 244.35% [2]. - Shenzhou Cell down 5.14% with a market cap of 22.9 billion and a year-to-date increase of 42.06% [2]. - Wanbangde (002082) down 5.07% with a market cap of 8.71 billion and a year-to-date increase of 121.46% [2].

Group 1 - The core viewpoint of the article highlights a collective decline in the A-share market for innovative drug concept stocks, with significant drops in several companies [1] Group 2 - Changshan Pharmaceutical experienced a decline of over 19%, with a total market capitalization of 51.7 billion and a year-to-date increase of 181.54% [2] - Zicheng Pharmaceutical and Baiyang Pharmaceutical both fell by over 7%, with market capitalizations of 6.984 billion and 13.3 billion respectively, and year-to-date increases of 68.53% and 9.05% [2] - Other companies such as Bibete-U, Kangchen Pharmaceutical, and Kanghong Pharmaceutical saw declines exceeding 5%, with market capitalizations of 14.3 billion, 28.8 billion, and respective year-to-date increases of 79.30% and 62.53% [2] - The article also notes that MACD golden cross signals have formed, indicating potential upward momentum for some stocks [1]

Group 1 - The core point of the news is that Kanghong Pharmaceutical experienced a decline of 5.01% in its stock price, reaching 31.46 CNY per share, with a trading volume of 231 million CNY and a turnover rate of 1.05%, resulting in a total market capitalization of 28.985 billion CNY [1] - Kanghong Pharmaceutical, established on October 3, 1996, and listed on June 26, 2015, is based in Chengdu, Sichuan Province, and its main business involves the research, production, and sales of chemical drugs, traditional Chinese medicine, and biological products [1] - The revenue composition of Kanghong Pharmaceutical is as follows: biological drugs account for 54.83%, traditional Chinese medicine 32.49%, chemical drugs 12.50%, and other categories 0.15% [1] Group 2 - Morgan Fund has a significant holding in Kanghong Pharmaceutical, with the Morgan Healthcare Stock A fund (001766) holding 509,000 shares, representing 3.43% of the fund's net value, making it the tenth largest holding [2] - The Morgan Healthcare Stock A fund was established on October 21, 2015, with a current size of 545 million CNY, and has achieved a year-to-date return of 27.08%, ranking 2118 out of 4216 in its category [2] - The fund manager, Ye Min, has been in charge for 3 years and 102 days, with the fund's total assets amounting to 1.861 billion CNY, achieving the best return of 40.74% and the worst return of -5.8% during his tenure [2]